Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ALDH1B1 | P30837 | 1/20 | 0.37 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | AGXT | P21549 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3193515 | 0.91 | KDM4E (0.41) | FAAHTAAR1CHRM2CHRM1CHRM3 | |
| SCHEMBL4859900 | 0.87 | TAAR1 (0.56) | TAAR1CHRM2CHRM1CHRM3IDO1 | |
| SCHEMBL3593702 | 0.83 | IDO1 (0.46) | FAAHCA1CA2CA9ALDH1A2 | |
| SCHEMBL9191664 | 0.83 | KDM4E (0.46) | FAAHTAAR1PPARGPPARAALDH1A1 | |
| SCHEMBL27920227 | 0.82 | TAAR1 (0.62) | CA1CA2CA9TAAR1DRD2 | |
| SCHEMBL13454202 | 0.82 | FAAH (0.43) | FAAHCA1CA2CA9TAAR1 | |
| SCHEMBL6941013 | 0.82 | CYP4F2 (0.53) | FAAHTAAR1ALDH1A1 | |
| SCHEMBL28747906 | 0.82 | FAAH (0.43) | FAAHCA1CA2CA9TAAR1 | |
| SCHEMBL6761017 | 0.82 | MGLL (0.44) | FAAHALDH1A2ALDH1A1ALDH1B1ALDH1A3 | |
| SCHEMBL9854763 | 0.81 | PPARG (0.46) | CA1CA2CA9F2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9925182-B2 | Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound | NEKTAR THERAPEUTICS (US) | 2018-03-27 | — | — | US | disclosed |
| US-9827239-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170112826-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2017-04-27 | — | — | US | disclosed |
| US-20170079975-A1 | Compositions, Dosage Forms, and Co-Administration of an Opioid Agonist Compound and an Analgesic Compound | NEKTAR THERAPEUTICS | 2017-03-23 | — | — | US | disclosed |
| US-9512135-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2016-12-06 | — | — | US | disclosed |
| US-9457024-B2 | Compositions, dosage forms, and co-administration of an opioid agonist compound and a non-steroidal anti-inflammatory drug | NEKTAR THERAPEUTICS | 2016-10-04 | — | — | US | disclosed |
| US-9458166-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160130276-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2016-05-12 | — | — | US | disclosed |
| US-9233167-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150238624-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2015-08-27 | — | — | US | disclosed |
| US-8952032-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140336214-A1 | Compositions, Dosage Forms, and Co-Administration of an Opioid Agonist Compound and an Analgesic Compound | NEKTAR THERAPEUTICS | 2014-11-13 | — | — | US | disclosed |
| US-8569343-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2013-10-29 | — | — | US | disclosed |
| US-8440687-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120289548-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120264775-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2012-10-18 | — | — | US | disclosed |
| US-6288096-B1 | ANTIDIABETIC AGENTS, HYPOTENSIVE AGENTS, AND ANTICHOLESTEROL AGENTS | ASTRAZENECA AB (SE) | 2001-09-11 | — | — | US | disclosed |
| EP-0991632-A1 | NEW THIAZOLIDINEDIONE, OXAZOLIDINEDIONE AND OXADIAZOLIDINEDIONE DERIVATIVES | Astra Aktiebolag (SE) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998057941-A1 | NEW THIAZOLIDINEDIONE, OXAZOLIDINEDIONE AND OXADIAZOLIDINEDIONE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1998-12-23 | — | — | WO | disclosed |
| EP-0428423-A2 | Aryloxy alkyl benzenes, processes for their preparation and pharmaceutical compositions containing them | LIPHA S.A. (FR) | 1991-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112826-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | FAAH 803/4885CA1 3927/4885CA2 4481/4885 |
| US-20170079975-A1 | Compositions, Dosage Forms, and Co-Administration of an Opioid Agonist Compound and an Analgesic Compound | OPRL1, OPRM1, OPRK1 | FAAH 282/4885CA1 3572/4885CA2 1893/4885 |
| US-20150238624-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | FAAH 803/4885CA1 3927/4885CA2 4481/4885 |
| US-20140336214-A1 | Compositions, Dosage Forms, and Co-Administration of an Opioid Agonist Compound and an Analgesic Compound | OPRL1, OPRM1, OPRK1 | FAAH 282/4885CA1 3572/4885CA2 1893/4885 |
| US-20160130276-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | FAAH 803/4885CA1 3927/4885CA2 4481/4885 |
| US-20120289548-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | FAAH 803/4885CA1 3927/4885CA2 4481/4885 |
| US-20120264775-A1 | Oligomer-Opioid Agonist Conjugates | OPRM1, OPRL1, OPRK1 | FAAH 803/4885CA1 3927/4885CA2 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.